Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?

Serena Colafrancesco, Cristiano Alessandri, Fabrizio Conti⁎, Roberta Priori

Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari, Rheumatology Unit, Sapienza University of Rome, Rome, Italy

ARTICLE INFO

Keywords:
COVID-19
Cytokine storm
Inflammation
Ferritin

ABSTRACT

The severe form of COVID-19 share several clinical and laboratory features with four entities gathered under the term “hyperferritinemic syndromes” and including macrophage activation syndrome (MAS), adult-onset Still’s disease (AOSD), catastrophic anti-phospholipid syndrome (CAPS) and septic shock. COVID-19 systemic inflammatory reaction and “hyperferritinemic syndromes” are all characterized by high serum ferritin and a life-threatening hyper-inflammation sustained by a cytokines storm which eventually leads to multi-organ failure. In this review, we analyze the possible epidemiological and molecular mechanisms responsible for hyper-inflammation in patients with severe COVID-19 and we underline the similarities between this condition and “hyperferritinemic syndromes” which would allow considering severe COVID-19 as a fifth member of this spectrum of inflammatory conditions.

1. Introduction

The umbrella term “hyperferritinemic syndromes” encompasses four clinical conditions, including macrophage activation syndrome (MAS), adult-onset Still’s disease (AOSD), catastrophic anti-phospholipid syndrome (CAPS), and septic shock, all characterized by high serum ferritin and a life-threatening hyper-inflammation sustained by a cytokines storm which eventually leads to multi-organ failure [1]. In March 2020, the World Health Organization declared COVID-19, the disease-associated to the novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, a pandemic. A significant amount of COVID-19 patients is currently experiencing severe interstitial pneumonia possibly ending up with acute respiratory distress syndrome (ARDS) and systemic inflammatory response syndrome (SIRS). This severe form of COVID-19 shares several clinical and laboratory features with the four entities mentioned above and currently included in the definition of “hyperferritinemic syndromes” [2]. This concept may guide and support therapeutic choices as all these entities respond to a similar approach consisting of anti-inflammatory and immunomodulatory agents such as glucocorticoids, IVIg, cyclosporin, IL-1 and IL-6 inhibition [1,2]. Plasmapheresis or IL-18 blockade may be considered as well [1,3]. Some preliminary results confirm the beneficial effects of Tocilizumab in COVID-19 [4] and current recommendations [5] advocate its use in those patients evolving toward the most severe stage of illness characterized by an extra-pulmonary systemic hyper-inflammation [6].

The idea of a third later stage of COVID-19 as the dramatic result of an overwhelming cytokine storm [7] is strengthened by the observation of the increased level of different molecules including IL-1β, IL-1RA, IL-7, IL-8, IL-9, IL-10, fibroblast growth factor (FGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IFNγ, granulocyte-colony stimulating factor (G-CSF), interferon-γ-inducible protein (IP10), monocyte chemoattractant protein (MCP1), macrophage inflammatory protein 1 alpha (MIP1A), platelet-derived growth factor (PDGF), tumor necrosis factor (TNFα) and vascular endothelial growth factor (VEGF) [8,9]. Especially in severe cases, IL-2, IL-7, IL-10, G-CSF, IP10, MCP1, MIP1A, and TNFα seem to be extremely high [8,9] and significant elevation of IL-6 in non-survival patients has been described [10].

2. Clinical, laboratory and autoptic similarities: COVID-19 vs hyperferritinemic syndromes

The main clinical and laboratory features characterizing patients with hyperferritinemic syndromes are described in Table 1 and compared with COVID-19 severe manifestations. As already mentioned, in addition to cytokine profile, other features make COVID-19 similar to the members of the hyperferritinemic syndromes, at least in some of their stages: lymphopenia, reduced NK number and activity, abnormal

⁎ Corresponding author at: Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Rheumatology Unit, Policlinico Umberto I, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.

E-mail address: fabrizio.conti@sapienza.it (F. Conti).

https://doi.org/10.1016/j.autrev.2020.102573
Received 11 April 2020; Accepted 12 April 2020
Available online 05 May 2020
1568-9972/ © 2020 Elsevier B.V. All rights reserved.
liver function tests, coagulopathy and of course hyperferritinemia [1,11].

Hyperferritinemia is the hallmark of the “ hyperferritinemic syndromes ” and along the last decade, increasing evidence supports the idea that high circulating ferritin may not only reflect an acute phase response but also play a critical role in inflammation [12]. Ferritin is a major intracellular iron storage protein and the ratio between its two subunits, H and L, may differ depending on tissue type and physiologic status of the cell [13]. H-ferritin seems to display not only an immunomodulatory function [14,15] but also a pro-inflammatory activity culminating with the induction of the expression of different inflammatory mediators, including IL-1β [16]. Hyperferritinemia characterizes several autoimmune diseases [17] where it may play a pathogenetic role on the ground of its immunomodulatory properties [12]. The origin of circulating serum ferritin during inflammatory conditions is still debated. In vitro experiments demonstrated that ferritin might be actively secreted by hepatocytes [18] as well as by macrophages through a non-classical pathway [19]. Thus, it is likely that in “ hyperferritinemic syndromes ” macrophage activation could actively contribute to ferritin production. In line with this hypothesis, in a previous study, we demonstrated that in AOSD ferritin serum levels are not only correlated with disease activity, but also with macrophage activation [20]. Interestingly, in a very recent study describing a cohort of 39 hospitalized patients with COVID-19, ferritin serum levels were found significantly correlated with disease severity [21]. Besides an active secretion, during the inflammatory reaction, a major component of serum ferritin derives by cellular death and, in particular, by hepatic cells death. Once released, ferritin loses part of the inner iron content other features, such as the classical organomegaly, is remarkable, has several abnormal laboratory parameters similar to MAS, the lack of DIC is also a major complication the other hyperferritinemic syndromes including AOSD [27], MAS [28], sepsis [29] and, of course, CAPS. Infection induces increased coagulation by two different effects: by activating the cascade coagulation system and by downregulating the anti-coagulant mechanisms [29]. The endothelial cell and platelet activation occurring in CAPS is a key contributor to the genesis of a “thrombotic storm” [30] and in this setting, it is remarkable the role of infections as triggers of the disease [31]. It is of note that three Chinese COVID-19 patients admitted to ICU and presenting thrombotic events tested positive for antiphospholipid antibodies as well as anti–β2 glycoprotein I IgA and IgG antibodies [32]. However, as noted by Mc Gonagle D and coll, the increased vascular coagulation occurring in COVID-19 patients is more close to a lung centric pulmonary intravascular coagulopathy (PIC) rather than a classical DIC [32]. This peculiar presentation seems related to a MAS-like intra-pulmonary inflammation. Indeed, although severe COVID-19 has several abnormal laboratory parameters similar to MAS, the lack of other features, such as the classical organomegaly, is remarkable, leading to suppose a hyper-activation of the immune system mainly confined to the lung parenchyma [33].

Further similarities between “ hyperferritinemic syndromes ” and SARS-CoV-2 severe infection are revealed from the few autopsies on COVID-19 patients reported so far. Macroscopic features in autopsies include pleurisy, pericarditis, lung consolidation, pulmonary edema [34]; microscopic findings include diffuse alveolar damage with inflammatory infiltrates composed mainly by monocytes and macrophages, but minimal lymphocytes infiltration, and multinucleated giant cells alongside large atypical pneumocytes [11,35]. Cardiac involvement in the form of myocarditis has been also described [36]. Similarly, pleurisy, pericarditis and myocarditis have been largely described in patients with AOSD and MAS [37,38]. Some recommendations and guidelines to safely perform autopsies in COVID-19 patients have been published [39] but the literature on this aspect is still poor even if
pathological aspects are of utmost importance to better understand the extent and type of damage associated with this infection and its possible pathogenesis.

3. Molecular and epigenetic factors implicated in COVID-19 induced systemic inflammation

Why some patients with SARS-CoV-2 infection evolve to a hyper-inflammation state with such a dramatic course while others seem to respond to treatment, is still unknown. The severity of its evolution does not seem exclusively ascribable to viral factors, but probably to host features including different epidemiologic and molecular factors (Fig. 1). Among them, the presence of an age and sex preference is evident with a higher occurrence of severe inflammation especially in elders and men [40]. The different lung expression of the ACE2 molecule, the receptor used by COVID-19 to enter cells, could be one of the reasons responsible for a higher prevalence of the severe disease in this specific subset of patients [41]. Accordingly, specific therapies modulating the expression of this receptor such as ACE inhibitors or angiotensin receptor blockers could be considered an additional external factor providing a major risk for patients. Co-morbidities represent an ulterior risk factor for the development of severe COVID-19 systemic inflammation and among them, type II Diabetes is one of the mostly described. To this regard, the increased expression of another receptor named human dipeptidyl peptidase 4 (DPP4), highly expressed in patients with type II Diabetes, might be implicated in the worst disease outcome do to the possible ability of SARS-CoV-2 to infect cells through DPP4 binding, as already described in MERS-CoV infection [42].

Despite the lack of specific data on COVID-19, ethnicity might also have some impact on virus infection outcome. At birth, differences in innate immune response between Caucasian and Asian people have been identified [43]. Macrophages derived from healthy Filipinos and challenged with M. Tuberculosis, demonstrate a lower production of IL-1 and IL-6 as well as higher production of IL-8, compared to Chinese and non-Hispanic white people [44]. Additionally, studies on PBMC from children vaccinated for measles showed race-related variation in the amount of cytokine produced following stimulation [45].

Another fascinating hypothesis supporting the differences in COVID-19 infection outcome is an antibody-dependent enhancement of SARS-CoV2 due to previous exposure to other coronavirus [46]. Indeed, previous contact with other coronaviruses responsible for a boost in immune response before COVID-19 infection could be accountable for the differences in disease severity observed among people.

What is sure right now is that for reasons that still need to be clarified, in some COVID-19 patients there is an over-inflammatory reaction, which strictly reminds the one observed in other inflammatory conditions, such as AOSD, which is a prototype of idiopathic autoinflammatory disorder frequently triggered by infections [47]. Due to similarities with this condition, a genetic predisposition cannot be excluded as well. In AOSD, the presence of rare coding variants in IL-1 related pathways [48] and gene polymorphism associated with IL-18 [49] have been identified. At the same extent, heterozygous mutations related to PRF1 and UNC13D genes, have been linked to a specific subset of MAS patients [50].

Besides genetic factors, the modulation of the expression of different cytokines both by lung epithelial cells and by innate and adaptive immune cells needs to be taken into account. Regarding IL-1ß, it is important to remind that previous studies on SARS-CoV demonstrated the ability of the virus to up-regulate inflammasome activity with consequent capacity to actively increase the production of IL-1ß [51]. Due to the similarities between SARS-CoV and SARS-CoV-2 (82% nucleotide sequence homology), it is likely that SARS-CoV-2 displays the same capacity to induce an exaggerated IL-1ß mediated response. Thus, the link between COVID-19 induced inflammatory reaction and hyperferritinemic syndromes, such as AOSD or MAS, is immediately
evident being both related to a massive IL-1β systemic release. During MAS, it is also important to remind the role of type II interferon (IFN), which is a crucial mediator of the inflammatory response and whose neutralization looks promising [52]. In this regard, although it is known that type I IFN represents the main anti-viral pathway, studies on SARS-CoV revealed that both type I and type II IFN (alpha-beta and gamma) synergize to inhibit virus replication with a concomitant active virus attempt to reduce such IFN production [53]. Preliminary data from COVID-19 patients suggest how a suppressed IFN-γ production by CD4+ T cells is associated with more severe disease [54]. Nonetheless, in the advanced stages of the disease, an over-expression of this molecule may occur, due to a second “wave” of systemic inflammatory reaction similar to MAS. For this reason, a clinical trial evaluating the efficacy of concomitant inhibition of IL-1 (Anakinra) and IFN (emapalumab) in severe COVID-19 patients has just started (NCT04324021). However, in patients with COVID-19, a clear distinction between ARDS and MAS is challenging, especially in the first phases of the disease where ARDS represents the main source of IL-6 and IL-1 [33]. Results from Anakinra/Emapalumab trial will surely provide interesting insights on COVID-19 associated “MAS like-syndrome”.

Besides IL-1β, the majority of studies published up to now suggests a predominant role of IL-6 in severe COVID-19 inflammatory reaction. In patients with ARDS, the lung epithelium and immune cell hyper-expression of IL-6 is associated with a poor disease outcome [55], as confirmed by a recent study on COVID-19 patients [56]. However, IL-6 is also a crucial regulator of the balance among fibroblasts, macrophages, and epithelial lung cells and is able to participate in the resolution of inflammation [57]. Thus, a prolonged therapeutic blockade of this cytokine and the exact timing to do that needs to be carefully considered [33].

Finally, regarding other epidemiological factors possibly able to influence disease outcome, the use of concomitant immune modulating/immune-suppressive therapies is certainly critical [58]. Interestingly, preliminary observations point out that immunosuppressed heart-transplanted patients present a milder form of COVID-19 during the later stages when the clinical evolution is mediated by the host inflammatory response [59,60]. At the moment, the Italian Society of Rheumatology has organized a national registry to gather information regarding patients with immune-rheumatologic disease infected by SARS-CoV-2 and the European League Against Rheumatism (EULAR) has proposed a similar registry too. Very preliminary results on a large cohort of Italian patients with chronic arthritis treated with immunosuppressive agents (biologic and targeted synthetic DMARDs), showed no increased risk of respiratory or life-threatening complication from SARS-CoV-2 infection. Despite the limited follow-up and the small number of cases that do not allow to draw any conclusion, the results could suggest a possible benefit of immune suppression in these patients, possibly preventing the onset of uncontrolled systemic inflammation [61]. Collection and further analysis of such information will be of great interest for the future.

4. Conclusions

In conclusion, we believe that COVID-19 systemic inflammation is part of the spectrum of hyperferritinemias. A common pathogenetic background is probably underlying to these conditions supporting the use of therapies that target crucial inflammatory mediators. To date, several clinical trials evaluating the efficacy of IL-6 inhibition by Tocilizumab or Sarilumab, and IL-1 inhibition by Anakinra or Canakinumab are ongoing (Clinical trial.gov; EU Clinical Trial Registry; Chinese Clinical trial registry; Iranian Registry of Clinical trials). Response to these therapies, known to display a significant benefit especially in AOSD [62,63] and MAS [64], will further support the hypothesis of a strict pathogenic connection between “hyperferritinemias” and severe COVID-19.

Contributions of each author

R. Priori had the idea, organized and partly wrote the article, and reviewed it.

S. Colafrancesco critically reviewed the literature and wrote most of the article.

C. Alessandri and F. Conti discussed the topic, contributed to the review of the literature, reviewed the article.

Declaration of Competing Interest

The Authors have neither financial interests nor have received financial support or benefits from commercial sources for the work reported on in the manuscript, which could create a potential conflict of interest or the appearance of a conflict of interest with regard to the present work.

References

[1] Rosário C, Zandman-Goddard G, Meyron-Holza EG, D’Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 2015;11:185.
[2] Shoenfeld Y. Coronavirus (COVID-19) time-musings: our involvement in COVID-19 pathology, diagnosis, treatment and vaccine planning. Autoimmun Rev 2020;20:102538.
[3] Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Köter I, et al. Open-label, multicenter, dose-escalating phase I clinical trial on the safety and efficacy of takedimp-alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis 2018;77(6):840-7.
[4] Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6K) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020;16:1595-4.
[5] Nicastri E, Petrosillo N, Bartoli TA, Lepore L, Mondi A, Palmieri F, et al. National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. recommendations for COVID-19 clinical management. Infect Dis Rev 2020;12:185-431.
[6] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Tattersall S. JLLH across speciality collaboration. UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–4.
[7] Gabay C, Kagnoff MF, Mebra M. IL-1β expression in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Lethal Transpl 2020. https://doi.org/10.1016/j.heart.2020.03.012.
[8] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
[9] Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydman I. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 2020;34;
[10] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054-62.
[11] Zhang W, Zhao Y, Zhang F, Wu Q, Li T, Liu Z, et al. Use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. Clin Immunol 2020; https://doi.org/10.1016/j.clim.2020.108393.
[12] Recalcati S, Invernizzi P, Arosio P, Cairo G. New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun 2008;30:84-9.
[13] Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996;1275:161–203.
[14] Moroz C, Grunspan A, Zaballa MA, Trabul L, Kodman Y, Yaniv I. Treatment of human bone marrow with recombinant placenta immunoregulator ferritin results in myelopoiesis and T-cell suppression through modulation of the cytokine-chemokine network. Exp Hematol 2006;34:159–66.
[15] Wigginton JM. Reversal of ferritin-mediated immunosuppression by levamisole: a rationale for its application to management of the acquired immune deficiency syndrome (AIDS). Med Hypotheses 1995;44:85–8.
[16] Ruedell RG, Hoang-Le D, Barwood JM, Rutherford PS, Piva TJ, Watters DJ, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepaticstellate cells. Hepatology 2009;49:887-900.
[17] Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev 2007;6:457–63.
[18] Ghosh S, Hevi S, Chuck SL. Regulated secretion of glycosylated human ferritin from hepatocytes. Blood 2004;103(6):2369–76.
[19] Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang DL, Crooks DR, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepaticstellate cells. Hepatology 2009;49:887-900.
[20] Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev 2007;6:457–63.
[21] Dahlan S, Katz I, Helleu T, Tietel M, Drobn Y, Bryk G, et al. A fatal correlation: ferritin
as a marker of severity in COVID-19 patients. Autoimmun Rev 2020. [In press].

[22] Petriotis E, Klé D. DB. Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases. Integr Biol (Camb) 2014;6(5):486–510.

[23] Lipinski B, Petriotis E, Oberholzer HM, Van Der Spuy WJ. Iron enhances generation of fibrin fibers in human blood: implications for pathogenesis of stroke. Micros Res Tech 2012;75(9):1185–90.

[24] Perricone C, Shoenfeld Y, Gerli R. COVID-19 as part of hyperferritinemic syndromes: implications for treatment. Autoimmun Rev 2020. [In press].

[25] Deng Y, Liu W, Liu K, Fang YY, Shang J, Zhou L, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin Med J (Engl) 2020. https://doi.org/10.1097/CM9.0000000000008284.

[26] Zhang Y, Cao W, Xiao M, Li YJ, Yang Y, Zhao J, et al. Clinical characteristics of 7 patients with critical COVID-19 pneumonia and aco- ischemia. Zhonghua Xue Ye Xue Za Zhi 2020;41(0):E006.

[27] Priori R, Colafrancesco S, Picarelli G, Di Franco M, Valesini G. Adult-onset Still’s disease: not always so good. Clin Exp Rheumatol 2012;30:142.

[28] Carrasco M, Mendoza-Pinto C, Macías-Díaz S, Vazquez de Lara F, Etchegary-Morales I, Galvez-Romero JL, et al. The role of infectious diseases in the catastrophic antiphospholipid syndrome. Autoimmun Rev 2015;14(11):1066–71.

[29] Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and anti- phospholipid antibodies in patients with COVID-19. N Engl J Med 2020. https://doi.org/10.1056/NEJMc2007575.

[30] McCombath D, Sharif K, O’Regan A. Bridgewood CA. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun Rev 2020;19:102537.

[31] Hanley B, Lucas SB, Youd E, Swift B, Oshorn M. Autopsy in suspected COVID-19 cases. J Clin Pathol 2020. https://doi.org/10.1136/jclinpath-2020-206522. pii: jclinpath-2020-206522.

[32] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8(4):420–3.

[33] Inciardi RM, Lui P, Zaccone G, Italio L, Raffo M, Tomasoni D. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020. https://doi.org/10.1001/jamacardio.2020.1096.

[34] Parisi F, Paglionicia A, Varrassio V, Ferraccioli G, Gremese E. Refractory adult-onset Still’s disease complicated by macrophage activation syndrome and acute myocarditis: a case report treated with high doses (8mg/kg/d) of anakinra. Medicine (Baltimore) 2017;96(24):e6656.

[35] Gerfaud-Valentin M, Sève P, Ivar J, Gagnard A, Broussole C, Durieu I, et al. Myocarditis in adult-onset Still disease. Medicine (Baltimore) 2014;93(17):1395–405.

[36] Osborn M, Lucas S, Stewart R, Swift B, Oshorn M. Autopsy practice relating to possible cases of COVID-19 (2019-nCov, novel coronavirus from China 2019/2020). The Royal College of Pathologists. 2020https://www.rcpath.org/uploads/assets/2de52baaf5-78af-4b0c-ac6e-3760e6e223/457c37d2-9d4d-4994-a11e287993de0905/Briefing-on-COVID-19-autopsy-Feb-2020.pdf.

[37] Yang J, Zheng Y, Gao X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus COVID-19 infection: a systematic review and meta-analysis. Int J Infect Dis 2020. https://doi.org/10.1016/j.ijid.2020.03.017. pii: S1201-9712(20)30316-3.

[38] Imai Y, Kubo K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005;436(7047):112–6.

[39] Jacobson RM, et al. Associations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vacci-nation. Viral Immunol 2012;20(2/3):1-29–36.

[40] Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect 2020;22(2):72–3.

[41] Gerfaud-Valentin M, Jamilous Y, Ivar J, Sève P. Adult-onset Still’s disease. Autoimmun Rev 2014;13(7):708–22.

[42] Cavalli G, van Deuren R, Arts P, Steehouwer M, Gilsen C, Sfiroa P, et al. Identification of rare coding variants in Il-1-related pathways in patients with adult-onset Still’s disease. Ann Rheum Dis 2018;77(Suppl2):190. https://doi.org/10.1136/annrheumdis-2018-eular.3454.

[43] Sugiura T, Kagawa Y, Harigai M, Terajima-Ichida H, Kitamura Y, Furuya T. Association between adult-onset Still’s disease and interleukin-18 gene poly-morphisms. Gene Immun 2002;7:394–9.

[44] Crayne CB, Albeituni S, Nichols KE, Garry RF. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-asso- ciated coronavirus (SARS-CoV). Virology 2004;329(1):11–7.

[45] Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features in severe and moderate Coronavirus Disease 2019. J Clin Invest 2020. https://doi.org/10.1172/JCI137244. pii: JCI137244.

[46] Meduri GU, Kohler G, Headley S, Tolley E, Stenzt P, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 1995;108(5):1303–14.

[47] Uibaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 pro-gression. Med Mal Infect 2020. https://doi.org/10.1051/med mal/202004.002. pii: S0399-077X(20)30088-3.

[48] Yang NL, Wang CY, Yang SJ, Yu CH, Chen SH, Wu CL, et al. IL-6 ameliorates acute lung injury in influenza virus infection. Sci Rep 2017;7:43829.

[49] Spinelli FR, Ceccarelli F, Di Franco M, Conti F. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic. Ann Rheumatic Dis 2020. https://doi.org/10.1136/annrheumdis-2020-217387.

[50] Li F, Cai J, Dong N. First cases of COVID-19 from China. J Heart Lung Transplant 2020. https://doi.org/10.1016/j.healun.2020.03.006.

[51] Adlam S, Mehla MR. COVID-19: yet another coronavirus challenge in heart transplant. J Heart Lung Transplant 2020. https://doi.org/10.1016/j.healun.2020.03.007.

[52] Monti S, Balduzzi S, Delvani P, Belloi E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with im-munosuppressive targeted therapies. Ann Rheum Dis 2020. https://doi.org/10.1136/annrheumdis-2020-217424. pii: annrheumdis-2020-217424.

[53] Colafrancesco S, Manara M, Bortoluzzi A, Serban T, Bianchi G, Cantarini L, et al. Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts. Arthritis Res Ther 2019;21(1):275.

[54] Ma Y, Wu M, Zhang X, Xia Q, Yang J, Xu S, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still’s disease: a meta-analysis. Mod Rheumatol 2019;28(5):89–97.

[55] Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 2016;12(5):259–68.

[56] Bhattacharya PK, Ghassemi BJ, Nichols M, Kim R, Jerome KR, Nallai AK, et al. Coronavirus critical illness in patients with chronic obstructive pulmonary disease. JAMA. 2020. https://doi.org/10.1001/jama.2020.4326.

[57] Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606. https://doi.org/10.1136/bmj.m606.